Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross-Sectional Analysis From the VOLTAIRE Study.

Diabetes, obesity & metabolism·2026
Same author

Time as the language of behavior: Events, sequences, patterns and meanings.

Journal of neuroscience methods·2026
Same author

Thalamic 5-HT<sub>2A</sub> receptor activation reduces GABA uptake, increases tonic GABA<sub>A</sub> inhibition and induces absence seizures in Wistar rats.

Neuropharmacology·2026
Same author

Evaluation of Polygenic Scores and CT Imaging in Risk Factor Modification in Patients With Diabetes: Rationale and Design of the VOLTAIRE Study.

Clinical cardiology·2026
Same author

Debridement, Antibiotics and Implant Retention in the Management of Periprosthetic Joint Infection: One-Year Outcomes, Epidemiology and Predictors of Failure.

Journal of clinical medicine·2026
Same author

Syndecan-1, endocan and non-culprit coronary plaque composition following non-ST elevation myocardial infarction.

International journal of cardiology. Heart & vasculature·2026

Related Experiment Videos

Serotonin-dopamine interaction: an overview.

Ennio Esposito1, Vincenzo Di Matteo, Giuseppe Di Giovanni

  • 1Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri, Via Nazionale, 66030 Santa Maria Imbaro, Chieti, Italy. esposito@negrisud.it

Progress in Brain Research
|September 6, 2008
PubMed
Summary

Central dopamine and serotonin systems regulate behavior. Their dysfunction is linked to neuropsychiatric disorders like depression, schizophrenia, and Parkinson's disease.

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Central serotonergic (5-hydroxytriptamine, 5-HT) and dopaminergic (dopamine, DA) systems are crucial for regulating normal and abnormal behaviors.
  • Evidence suggests that neurotransmission dysfunction in these systems may contribute to the pathophysiology of various neuropsychiatric disorders.

Purpose of the Study:

  • To explore the role of central dopaminergic and serotonergic systems in behavioral regulation.
  • To investigate the potential link between dopamine and serotonin neurotransmission dysfunction and neuropsychiatric disorders.

Main Methods:

  • Review of existing literature on central neurotransmitter systems.
  • Analysis of studies investigating the involvement of dopamine and serotonin in behavioral control.
  • Examination of evidence linking neurotransmitter dysfunction to specific neuropsychiatric conditions.

Main Results:

  • Confirmed the critical role of central serotonergic and dopaminergic systems in behavioral regulation.
  • Identified dysfunction in DA and 5-HT neurotransmission as a potential factor in the pathophysiology of numerous neuropsychiatric disorders.
  • Highlighted the relevance of these systems in conditions such as depression, schizophrenia, ADHD, drug abuse, Tourette's syndrome, and Parkinson's disease.

Conclusions:

  • Central dopaminergic and serotonergic systems are fundamental to understanding normal and abnormal behaviors.
  • Neurotransmitter imbalances in DA and 5-HT pathways are implicated in the development of significant neuropsychiatric disorders.
  • Further research into these systems may offer novel therapeutic targets for treating these conditions.